Trial Profile
A Multi-arm, Phase 2 Study to Evaluate the Safety and Efficacy of Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Progressed on Second Generation AR-Directed Therapy
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Aug 2023
Price :
$35
*
At a glance
- Drugs Sacituzumab govitecan (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 13 Sep 2022 Interim Results (n=20)presented at the 47th European Society for Medical Oncology Congress
- 03 Aug 2022 Planned End Date changed from 1 Jun 2024 to 1 Jun 2026.
- 03 Aug 2022 Planned primary completion date changed from 1 Aug 2022 to 1 Aug 2024.